US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

37.88

+0.63001.69%

Post-market: 37.880.00000.00%19:30 EDT

Volume:52.02K

Turnover:1.97M

Market Cap:342.44M

PE:- -

High:37.97

Open:37.82

Low:37.60

Close:37.25

52wk High:39.80

52wk Low:30.66

Shares:9.04M

Float Shares:9.04M

Volume Ratio:0.80

T/O Rate:0.58%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Amgen Stock Forecast: AMGN Reclaims $410 as Pipeline Catalysts Build

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology

EGFR Exon 20 Insertion Race Heats Up: Furmonertinib Files First-Line Indication as Two Domestic Contenders Prepare for Head-to-Head Battle

MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

Hong Kong Market Flash: DUALITYBIO-B (09606) Surges Over 9% on Encouraging WCLC Abstract for DB-1311 Combo, First-Line SCLC ORR Hits 92.3%

Innovative Drugs Face a Key Data Catalyst Window! Can't Tell OS, PFS, and ORR Apart? Here's a Quick Reference Guide! Save It for Later

Yen Rally at a Crossroads as $103 Billion Short Position Looms Over Key Support Level

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Press Release: Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage

Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved

Press Release: Antengene Announces 2026 Interim Results: Achieves First

The $3 billion short squeeze: anatomy of crypto’s biggest liquidation event since 2021

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement

Bitcoin price breaks past $68K as $1B short squeeze hits

Press Release: Immatics Announces Second Quarter 2026 Financial Results and Business Update

Virgin Trains gets green light for channel tunnel route

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/ORR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":37.88,"timestamp":1790971200000,"preClose":37.25,"halted":0,"volume":52018,"hourTrading":{"tag":"盘后","latestPrice":37.88,"preClose":37.88,"latestTime":"19:30 EDT","volume":537,"amount":20341.56,"timestamp":1790983804845,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.016912751677852417,"floatShares":9040000,"shares":9040000,"eps":0,"marketStatus":"Market Closed","change":0.63,"latestTime":"10-02 16:00:00 EDT","open":37.82,"high":37.9699,"low":37.6,"amount":1965631.8915940002,"amplitude":0.00993,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":37.25,"sharesOutstanding":12900000,"nav":37.48,"aum":338819200,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":37.88,"preClose":37.88,"latestTime":"19:30 EDT","volume":537,"amount":20341.56,"timestamp":1790983804845,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.798571665918667,"impliedVol":0.202,"impliedVolPercentile":0.7043},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9040000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.798571665918667,"shares":9040000,"dividePrice":0,"high":37.9699,"amplitude":0.00993,"preClose":37.25,"low":37.6,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":37.88,"eps":0,"divideRate":0,"volume":52018,"delay":0,"ttmEps":0,"open":37.82,"prevYearClose":34.16,"prevWeekClose":38.3781,"prevMonthClose":37.77,"prevQuarterClose":37.77,"fiveDayClose":38.3781,"twentyDayClose":39.1754,"sixtyDayClose":36.83},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672923729","title":"Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2672923729","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672923729?lang=en_us&edition=fundamental","pubTime":"2026-10-04 03:40","pubTimestamp":1791056400,"startTime":"0","endTime":"0","summary":"Media Release COPENHAGEN, Denmark; October 3, 2026 Treatment with Rina-S 120 mg/m every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/03/3374111/0/en/genmab-announces-rinatabart-sesutecan-rina-s-phase-2-rainfol-01-results-demonstrated-durable-and-clinically-meaningful-responses-in-patients-with-platinum-resistant-ovarian-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128525929.USD","LU2092937221.SGD","BK4080","PROC","ADC","BK4231","LU0310800379.SGD","LU0708994859.HKD","NETL","IE00BGHQF417.EUR","LU2360108059.USD","IE00B3CCJ633.GBP","LU2023250504.SGD","LU1267930573.SGD","LU1917777945.USD","LU1974910355.USD","IE00B2PGVK34.USD","XHB","BK4086","LU2298321311.HKD","LU2041044095.USD","LU0868494617.USD","OC","LU2106854487.HKD","LU0029864427.USD","LU2048586759.USD","ORR","BK4007","LU2023250843.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669646482","title":"Amgen Stock Forecast: AMGN Reclaims $410 as Pipeline Catalysts Build","url":"https://stock-news.laohu8.com/highlight/detail?id=2669646482","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669646482?lang=en_us&edition=fundamental","pubTime":"2026-09-23 23:00","pubTimestamp":1790175600,"startTime":"0","endTime":"0","summary":"Amgen rebounds to $410.24 as dazodalibep and IMDELLTRA strengthen the pipeline while $418.73 becomes the next technical test.\n","market":"other","thumbnail":"https://resource.tradingkey.com/uploads/20260923/AMGEN-82b57eea98fd4d6fa458e68c35b3ab95.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260923/AMGEN-82b57eea98fd4d6fa458e68c35b3ab95.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/analysis/stocks/us-stocks/262182585-stocks-amgen-stock-forecast-pipeline-410-breakout-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZNH","ORR","PBE","TSLG","LU1061106388.HKD","BGSX","AZN","TSLT","TSL","BIB","TSLP","TSLI","LU2242652126.USD","LU0868494617.USD","07766","ELOL","LU2468319806.SGD","TSLQ","AMGN","09766","09366","BBH","TSLL","TSII","07366","TLA","LU1571399168.USD","PJP","IE0009355771.USD","TSDD","TSLZ","BK7095","ORR.AU","TSLY","TEST","LU1983299246.USD","LU2237443549.SGD","TESC","TSLO","IBB","TSYY","IE0002141913.USD","TBXU","TSLR","TSLS","CRSH","TSLW","IBBQ","TESL","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669882142","title":"PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2669882142","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669882142?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078400,"startTime":"0","endTime":"0","summary":"39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor nave patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366230/37149/en/pds-biotech-announces-publication-of-versatile-002-phase-2-clinical-trial-results-of-pds0101-with-pembrolizumab-in-hpv16-positive-recurrent-and-or-metastatic-r-m-head-and-neck-canc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","IDNA","BK4585","BK4588","ORR","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108925192","title":"EGFR Exon 20 Insertion Race Heats Up: Furmonertinib Files First-Line Indication as Two Domestic Contenders Prepare for Head-to-Head Battle","url":"https://stock-news.laohu8.com/highlight/detail?id=1108925192","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108925192?lang=en_us&edition=fundamental","pubTime":"2026-09-21 15:20","pubTimestamp":1789975238,"startTime":"0","endTime":"0","summary":"In the precision-targeted therapy space for non-small cell lung cancer (NSCLC), EGFR exon 20 insertion mutations (ex20ins) have long been viewed as one of the most difficult-to-treat niche targets...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","IPOS","BK4195","BK4211","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667498364","title":"MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667498364","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667498364?lang=en_us&edition=fundamental","pubTime":"2026-09-16 20:15","pubTimestamp":1789560900,"startTime":"0","endTime":"0","summary":"Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies U.S. expansion is funded by a $2.3 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/16/3363142/0/en/maia-biotechnology-doses-first-u-s-patient-in-ongoing-phase-2-non-small-cell-lung-cancer-clinical-trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPI","ORR","BK4107","IND","BK4139","LU2487616109.SGD","MAIA","BK4588","BK4585","L","LU0053666078.USD","LU0210528500.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157152624","title":"Hong Kong Market Flash: DUALITYBIO-B (09606) Surges Over 9% on Encouraging WCLC Abstract for DB-1311 Combo, First-Line SCLC ORR Hits 92.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157152624","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157152624?lang=en_us&edition=fundamental","pubTime":"2026-09-14 14:28","pubTimestamp":1789367315,"startTime":"0","endTime":"0","summary":"Shares of DUALITYBIO-B (09606) rallied sharply during Friday's session, climbing more than 9% at one point. As of the latest update, the stock was trading up 8.48% at HK$183, with turnover reaching...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","KCAI","BK4585","BK4588","ORR","HK0000252152.HKD","09606","BK1161","HK0000500386.USD","VXUS","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175331559","title":"Innovative Drugs Face a Key Data Catalyst Window! Can't Tell OS, PFS, and ORR Apart? Here's a Quick Reference Guide! Save It for Later","url":"https://stock-news.laohu8.com/highlight/detail?id=1175331559","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175331559?lang=en_us&edition=fundamental","pubTime":"2026-09-11 19:30","pubTimestamp":1789126250,"startTime":"0","endTime":"0","summary":"For innovative drug investors, a major event is on the horizon. This Saturday, September 12th, the 2026 WCLC (World Conference on Lung Cancer) opens its doors, with several leading innovative drug...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","LNGR","ORR","MEDX","BK1161","BK1574","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102380640","title":"Yen Rally at a Crossroads as $103 Billion Short Position Looms Over Key Support Level","url":"https://stock-news.laohu8.com/highlight/detail?id=1102380640","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102380640?lang=en_us&edition=fundamental","pubTime":"2026-09-04 11:42","pubTimestamp":1788493323,"startTime":"0","endTime":"0","summary":"During Friday's Asian trading session, the dollar-yen pair extended its downward slide, dipping to 155.29, its lowest level since August 4th, before stabilizing near the 156 handle. This price action...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTSI","PRMN","ORR","MTRA","WTLS","CLSE","SHRT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664587723","title":"AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS","url":"https://stock-news.laohu8.com/highlight/detail?id=2664587723","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664587723?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:25","pubTimestamp":1788441947,"startTime":"0","endTime":"0","summary":"AbbVie (ABBV) announced positive topline results from the Phase 3 Cervino study evaluating etentamig, an investigational BCMA x CD3 bispecific T-ce...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abbvie-announces-phase-3-cervino-study-met-dual-primary-endpoints-of-orr-pfs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abbvie-announces-phase-3-cervino-study-met-dual-primary-endpoints-of-orr-pfs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0057025933.USD","BK4559","GLAM","LU1093756325.SGD","IE00BJJMRZ35.SGD","ORR","LU2089284900.SGD","LU1929549753.HKD","SG9999011175.SGD","LU1244550494.USD","LU0912757837.SGD","VHT","IE000F7OJYX1.SGD","LU0472753341.HKD","LU0942090050.USD","LU0868494617.USD","LU1989772840.SGD","FHLC","LU1585245621.USD","LU0795875169.SGD","BK4550","LU0965509283.SGD","LU0417517546.SGD","PJP","LU0820561909.HKD","TRUH","FTXH","LU2129689431.USD","LU2357627491.SGD","ABBV","XLV","LU0882574055.USD","PPH","LU0203347892.USD","MEDX","BK4585","LU0256863811.USD","LU2237443465.HKD","JDOC","IYH","LU1496350171.SGD","IE00BLSP4239.USD","IXJ","LU0124676726.USD","IE000WAW04H5.SGD","LU1057294990.SGD","IE0004445239.USD","RXL","AGNG","LU0320765646.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663600336","title":"Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2663600336","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663600336?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:23","pubTimestamp":1788178980,"startTime":"0","endTime":"0","summary":"CS2009 Achieved Key Clinical Validations for Efficacy and SafetyAs of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient enrollment and longer follow-up, improvements were observed in both the objective response rate  and duration of response :Compelling monotherapy efficacy in first-line non-small cell lung cancer -- At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease. control rate  of 100% in patients with PD-L1 TPS >=50%. In the. broader PD--L1 TPS >=1% population, the ORR was 70.8% and DCR was 91.7%.Monotherapy efficacy in Immunotherapy -pretreated NSCLC and IO-nonresponsive \"cold tumors\" further validates CTLA-4 activity and efficacy.-- In second-line NSCLC patients (all previously treated with IO plus. -- In patients with heavily pretreated metastatic colorectal cancer ,CS2009 monotherap","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","LU1093756168.USD","XME","LU2211817866.USD","SIL","02616","ORR","IE00BFXG0V08.USD","BK4585","LU1223083913.SGD","L","IND","GDXJ","BK1161","IE00BYQQ9H92.USD","LU1721428933.USD","LU2487616109.SGD","LU0053666078.USD","BK4195","MTD","BK4211","IE00B5TLWC47.USD","BK4107","BK4121","BK4017","BK4588","LU2413666699.HKD","CDE","LU0347712357.USD","BK4567","SGDM","LU1223082196.USD","LU1093756325.SGD","BK4533","LU0210528500.USD","BK1574","LU2413666426.HKD","LU1223082519.USD","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662955085","title":"Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2662955085","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662955085?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:15","pubTimestamp":1787840100,"startTime":"0","endTime":"0","summary":"CS2009 Achieved Key Clinical Validations for Efficacy and SafetyAs of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient enrollment and longer follow-up, improvements were observed in both the objective response rate  and duration of response :Compelling monotherapy efficacy in first-line non-small cell lung cancer -- At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease. control rate  of 100% in patients with PD-L1 TPS >=50%. In the. broader PD--L1 TPS >=1% population, the ORR was 70.8% and DCR was 91.7%.Monotherapy efficacy in Immunotherapy -pretreated NSCLC and IO-nonresponsive \"cold tumors\" further validates CTLA-4 activity and efficacy-- In second-line NSCLC patients (all previously treated with IO plus. -- In patients with heavily pretreated metastatic colorectal cancer ,CS2009 monotherapy","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4017","BK4567","MTD","CDE","SIL","LU2413666426.HKD","BK4585","ORR","LU2413666699.HKD","L","LU1093756168.USD","LU1223082196.USD","LU2211817866.USD","PFS","IE00BFXG0V08.USD","LU1093756325.SGD","LU1223082519.USD","LU1721428933.USD","IE00BYQQ9H92.USD","SGDM","LU2487616109.SGD","XME","BK4107","GDXJ","BK1161","02616","LU0053666078.USD","BK4211","BK4588","BK1574","LU0347712357.USD","IE00B5TLWC47.USD","IND","LU0210528500.USD","LU1223083913.SGD","BK4548","BK4121","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085166","title":"Press Release: Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085166","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085166?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:05","pubTimestamp":1787839500,"startTime":"0","endTime":"0","summary":"established out-licensing agreements for innovative products, and strong. -- Profit for the period reached US$64.9 million, and adjusted net profit. for the period[1] was approximately US$71.6 million, marking seven","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4113","BK1161","BK4232","AAQC","ORR","R","MSS","CNS","BK1583","BK1574","BK4135","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662888737","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2662888737","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662888737?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:25","pubTimestamp":1787624700,"startTime":"0","endTime":"0","summary":"NANJING, China, Aug.  24, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s pr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350174/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-phase-ii-clinical-study-for-first-line-treatment-of-esophageal-squamous-cell-carcinoma-advances-to-expansion-stage.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBTY","EZBC","BTCZ","CBOJ","BTRN","CBTA","BCCC","BITY","BTCL","FBTC","BTF","DFII","GBTC","MAXI","ORR","BITO","DEFI","CBOY","BAGY","CBOO","QBF","BTCC","ARKB","BRRR","CBXO","HCC","PD","YBTC","ODD","XHB","BITB","BFJL","BETE","COAL","BFAP","OC","CBXY","HODL","XBTY","BITU","BPI","PFS","BTCW","MNRS","BITI","CBTJ","BITX","SBIT","BTC","CBOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661695272","title":"Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved","url":"https://stock-news.laohu8.com/highlight/detail?id=2661695272","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661695272?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:32","pubTimestamp":1787581920,"startTime":"0","endTime":"0","summary":"BEIJING, Aug. 24, 2026  -- InnoCare Pharma , a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the interim results and business highlights for the six months ended 30 June 2026.InnoCare delivered robust revenue growth and strengthened profitability in the first half of 2026, driven by strong commercial execution and global business development collaborations. In the first half of 2026, the Company's revenue grew by 55.5% year-on-year to RMB 1.1 billion, and profit reached RMB 239.7 million, a turnaround from a loss in the same period last year. These results reflect the successful implementation of the Company's strategy driven by innovation, commercialization and globalization.In the first half of 2026, InnoCare continued to accelerate innovation, achieving a series of key milestones.-- 1 NDA approval: Orelabrutinib was approved in Australia.-- 2 NDA acceptances: The NDA applications for orelabrutinib in primary. immune thrombocytopenia  a","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4195","IE00B5TLWC47.USD","SLE","ORR","BK1574","MTD","IE00BYQQ9H92.USD","BK4533","BK4567","BK4585","CR","ITP","LU1093756325.SGD","BK4121","LU2413666699.HKD","BK4161","LU2413666426.HKD","09969","LU2211817866.USD","IE00BFXG0V08.USD","BK1161","LU1721428933.USD","BK4199","BK4211","BK4588","LU1093756168.USD","BK4548","PFS","LU0347712357.USD","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661410992","title":"Press Release: Antengene Announces 2026 Interim Results: Achieves First","url":"https://stock-news.laohu8.com/highlight/detail?id=2661410992","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661410992?lang=en_us&edition=fundamental","pubTime":"2026-08-24 09:00","pubTimestamp":1787533200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Aug. 23, 2026 /PRNewswire/ -- Antengene Corporation Limited (\"Antengene\", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","LU2065731478.USD","BK4006","BK4187","ORR","BK1574","IE00B66KJ199.SGD","COAL","R","BK1583","IE0031619046.USD","IE00B19Z4B17.USD","06996","BK4022","CRS","BK1191","BK4232","PYZ","BK4585","XAR","CR","BK4588","03160","LU0963586101.USD","BK4555","BK4604","IE00B7SZL793.SGD","TM","BK4099","HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661525287","title":"The $3 billion short squeeze: anatomy of crypto’s biggest liquidation event since 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2661525287","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661525287?lang=en_us&edition=fundamental","pubTime":"2026-08-21 13:25","pubTimestamp":1787289926,"startTime":"0","endTime":"0","summary":"Six weeks of bearish positioning ended in 24 hours. Here is how the trade unwound, who got caught, and whether the squeeze has legs.More than $3 billion in leveraged short positions were liquidated across crypto derivatives markets on Aug 19 and 20, 2026, making it the eighth largest liquidation event on record and the largest concentrated short squeeze since November 2021.Bitcoin climbed from an intraday low near $64,100 to a peak above $72,000, while Ethereum surged roughly 18% in 24 hours, its strongest single day move since March 2024.The U.S. Treasury doubled the maximum size of its liquidity support buyback operations for long dated bonds from $2 billion to $4 billion per operation, compressing yields and pushing risk assets higher.Binance absorbed approximately $518 million in liquidations, Hyperliquid roughly $513 million, and Bybit around $303 million, with short positions accounting for 92% of all forced closures.Then, over the span of 24 hours, it went violently higher.Bitco","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"crypto_news_highlight","url":"https://crypto.news/3-billion-short-squeeze-anatomy-crypto-biggest-liquidation-2021-2/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/3-billion-short-squeeze-anatomy-crypto-biggest-liquidation-2021-2/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["BTF","EVNT","FTLS","BTC.USD.HKCC","ETHW","EETH","OSSL","LFGY","ETHA","HDGE","TON.USD.CC","YETH","HFEQ","CRPT","ETHU","RIVC","DWSH","LITU","BERZ","FETH","GDLC","GMEC","BKCH","WX","LSEQ","STCE","ETHD","ETU","09042","DIME","CLSE","TEKX","LBAY","BITW","ETHT","DAPP","MEMY","NCIQ","ORR","HELS","ETHE","IBIT","FFLS","EZET","SHRT","ETH","QETH","BTC.USD.CC","BITQ","ETHV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660770364","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement","url":"https://stock-news.laohu8.com/highlight/detail?id=2660770364","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660770364?lang=en_us&edition=fundamental","pubTime":"2026-08-20 10:53","pubTimestamp":1787194380,"startTime":"0","endTime":"0","summary":"NANJING, China, Aug.  19, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the full abstract of the Phase II clinic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/20/3348072/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-abstract-published-by-wclc-extended-follow-up-shows-continued-efficacy-improvement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBTY","GBTC","BITO","BTCI","BFJL","BITX","BTCC","IBIT","BITB","PFS","BTF","CBTO","PD","ODD","BTC","CBOA","BTCZ","SBIT","BITI","OC","BPI","BETE","BTRN","HODL","ORR","BITY","BFAP","CBXA","ARKB","BETH","YBTC","BAGY","BRRR","CBXJ","HCC","QBF","EZBC","BTCO","CBTA","MAXI","BTCW","CBXY","DFII","BTCL","CBOO","CBTJ","FBTC","DEFI","COAL","XHB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660473611","title":"Bitcoin price breaks past $68K as $1B short squeeze hits","url":"https://stock-news.laohu8.com/highlight/detail?id=2660473611","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660473611?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:29","pubTimestamp":1787171394,"startTime":"0","endTime":"0","summary":"Bitcoin price surged past $68,000 late Wednesday as a break above crowded liquidation levels forced short sellers to buy back positions, turning a gradual recovery into a one-minute price spike of roughly 4%.Bitcoin price jumped from below $65,000 to a high near $69,500 before settling around $68,500.More than $1 billion in crypto shorts were reportedly liquidated within one hour.The breakout cleared a 4-hour double-bottom neckline near $65,400.Bitcoin now faces daily resistance between $69,000 and $70,000 after its RSI entered overbought territory.Market analyst Daan Crypto Trades said in an Aug. 19 X post that Bitcoin experienced a “massive squeeze” after crossing the $67,000 liquidation cluster. He said the resulting one-minute candle gained about 4%, exceeding the size of any full daily candle recorded in recent weeks.Bitcoin reversed the setup within minutes. Once BTC price crossed $67,000, exchanges began closing positions that no longer had enough collateral, requiring short sel","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"crypto_news_highlight","url":"https://crypto.news/bitcoin-price-breaks-past-68k-as-1b-short-squeeze-hits/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/bitcoin-price-breaks-past-68k-as-1b-short-squeeze-hits/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["09042","STCE","HELS","BITK","MEMY","BITO","LSEQ","03008","IBIT","NCIQ","09008","OOQB","CBXJ","CLSE","CRPT","83042","BESO","IREC","LBAY","BTYB","03042","GMEC","CBTL","OSSL","RIVC","LITU","BTC","BERZ","BFOC","BITX","EVNT","CBXL","BTC.AU","ISBG","HDGE","FTLS","BTC.USD.HKCC","DWSH","WX","09439","HFEQ","03439","QBF","CBOL","SHRT","BTC.USD.CC","FFLS","SPBC","ORR","RIOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461968","title":"Press Release: Immatics Announces Second Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461968?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:00","pubTimestamp":1787050800,"startTime":"0","endTime":"0","summary":"-- Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene. autoleucel, IMA203) remains on track to complete the required. randomizations by year-end to support final analysis for the primary PFS. -- Company plans to proceed directly to a streamlined final analysis for the. primary endpoint, PFS, while strengthening power for the secondary. endpoint, OS, to enhance the commercial product profile. -- SUPRAME topline data disclosure for the final PFS analysis expected in H1. -- Anzu-cel PRAME Cell Therapy: Updated Phase 1b data at ASCO 2026 continued. to show durable anti-tumor activity in metastatic melanoma, with 56% cORR,of 46%, as well as predictable and manageable tolerability. -- IMA203CD8 PRAME Cell Therapy: Updated Phase 1 data presented at ASCO 2026. demonstrated clinical activity in hard-to-treat gynecologic cancers with. a 63% ORR and 50% cORR; updated data across multiple PRAME-positive solid. -- IMA402 PRAME Bispecific: Phase 1b data at recommended Phase 2 dose . r","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMTX","BK4139","PFS","BK4195","ORR","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660714484","title":"Virgin Trains gets green light for channel tunnel route","url":"https://stock-news.laohu8.com/highlight/detail?id=2660714484","media":"cityam","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660714484?lang=en_us&edition=fundamental","pubTime":"2026-08-17 18:45","pubTimestamp":1786963506,"startTime":"0","endTime":"0","summary":"Virgin will break up Eurostar's decades-old monopoly over channel crossings Virgin Trains has moved a step closer to running train services between London and Paris, Amsterdam and Brussels, after the railway watchdog waved through its application to use the line connected London to the channel tunnel.The Office of Rail and Road  said on Monday it had given Sir Richard Branson’s train company the green light to run as many as 20 return services to continental Europe from October 2030 onwards, in a decision likely to herald the break-up of Eurostar’s decades-old monopoly of the route. The ruling marks a significant milestone for Virgin Trains’ hopes to run a rival channel tunnel service, which were first announced last year. Virgin hailed it as an “opportunity to bring competition” to a route that has solely been operated by Eurostar since it was launched in 1994.","market":"fut","thumbnail":"https://www.cityam.com/wp-content/uploads/2026/08/Virgin-to-move-ahead-with-cross-Channel-plans.png?w=286&h=161&crop=1","type":0,"news_type":0,"thumbnails":["https://www.cityam.com/wp-content/uploads/2026/08/Virgin-to-move-ahead-with-cross-Channel-plans.png?w=286&h=161&crop=1"],"rights":{"source":"cityam_highlight","url":"https://www.cityam.com/virgin-trains-gets-green-light-for-channel-tunnel-route/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.cityam.com/virgin-trains-gets-green-light-for-channel-tunnel-route/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cityam_highlight","symbols":["ORR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":118,"code":"91000000","status":"200"}]}}